News

RIVANNA® Announces Partnership With BOMImed to Increase Distribution of Accuro® in Canada

RIVANNA®, developers of world-first, imaging-based medical solutions, announced they have entered into a partnership with BOMImed, a recognized manufacturer of anesthesia and critical care related consumables to represent and distribute the Accuro® portfolio of products in Canada.

BOMImed is a choice distribution partner for RIVANNA as its focus is within the fields of anesthesia and critical care, with company resources dedicated to providing the highest level of service inside of these markets.

Danielle Faulk, North America Director of Sales and Distribution at RIVANNA, commented, “This strategic partnership with BOMImed will efficiently enhance Accuro’s service offerings, attract new customers and expand coverage to a more expansive range of Canadian healthcare organizations. Our growing worldwide market adoption reflects Accuro’s value to its customers. It signifies a migration away from palpation-based needle placement in favor of a safer and more efficient image-guided standard for spinal needle placement.”

The Accuro spinal navigation system is designed to improve the efficiency of spinal needle guidance procedures using groundbreaking technology, including Multi-Frequency BoneEnhance® Image Reconstruction, which provides enhanced visualization of lumbar and thoracic bony anatomy, and SpineNav3D™ AI-Based Spine Recognition, which provides automated identification of spinal midline, epidural space and depth during lumber neuraxial anesthesia. This technology also supports real-time thoracic paramedian neuraxial procedures and prescribes a “needle-track” towards the interlaminar space. Relying on automated SpineNav3D™ technology, Accuro enables users with even minimal ultrasound experience to navigate the lumbar and thoracic spine and identify relevant landmarks used to compute, visualize and pinpoint the optimal needle insertion point.

David Olivier, President and CEO of BOMImed, said, “The BOMImed team is excited to introduce Accuro’s trailblazing technology to an expanding market supporting spinal needle guidance procedures in Canada. Accuro technology and its demonstrated clinical benefits underpin our mission to stay ahead of the curve in the products we sell and enhance the lives within the anesthesia and critical care community.”

Read more here.

Recent News

08/26/2025

Activation Capital Names Michael Steele as President and CEO

The Virginia Biotechnology Research Partnership Authority (doing business as Activation Capital) announced today that it has appointed Michael Steele as president and chief executive officer. Steele succeeds Robert Ward, who has served as interim CEO since July 2024 during a period of rapid growth for the life sciences ecosystem development organization. Steele comes to Activation

08/25/2025

Danforth Advisors Acquires PharmaDirections

Danforth Advisors LLC, today announced the acquisition of PharmaDirections, Inc., a full-spectrum development partner to life science companies, expanding its integrated capabilities from discovery through commercialization. Founded in 2003, PharmaDirections was a pioneer of the virtual drug development model. The company brings veteran program leaders and more than 150 specialists to support strategic planning and

08/22/2025

ivWatch Technology Linked to Major Reduction in Severe IV Injuries in Newborns Over Four-Year Study

A study published this month in The BMJ (British Medical Journal) analyzed the use of optical sensor technology from ivWatch, the U.S.-based IV safety company, in the early detection of peripheral intravenous infiltration or extravasation (PIVIE) events in neonates. Presenting a comparative evaluation between conventional observational methods and continuous sensor-based monitoring, the study offers insights